A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer

Cancer Investigation

Volumn 24, Issue 4, 2006, Pages 382-389

  Molina, Julian ^a   Nikcevich, Daniel ^b   Hillman, Shauna ^a   Geyer, Susan ^a   Drevyanko, Timothy ^c   Jett, James ^a   Verdirame, Joseph ^d   Tazelaar, Henry ^a   Rowland, Kendrith ^e   Wos, Edward ^f   Kutteh, Leila ^g   Nair, Suresh ^h   Fitch, Tom ⁱ   Flynn, Patrick ^j   Stella, Philip ^k   Adjei, Alex ^a  

^a MAYO CLINIC   (United States)

^b Duluth CCOP   (United States)

^c Iowa Oncology Research Association CCOP   (United States)

^d MISSOURI VALLEY CANCER CONSORTIUM   (United States)

^e Carle Cancer Center CCOP   (United States)

^f SANFORD RESEARCH   (United States)

^g Cedar Rapids Oncology Project CCOP   (United States)

^h GEISINGER MEDICAL CENTER   (United States)

ⁱ Scottsdale CCOP   (United States)

^j Metro Minnesota Community Clinical Oncology Program   (United States)

^k Michigan Cancer Research Consortium   (United States)

more..

Author keywords

Docetaxel; Irinotecan; NSCLC; Second line therapy

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; IRINOTECAN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DYSPNEA; EDEMA; EPISTAXIS; EVALUATION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMOPTYSIS; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; INFECTION; INTESTINE FISTULA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; SENSORY DYSFUNCTION; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 33745324935     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900600705318     Document Type: Article

References (36)

1. Bissery, M.C.; Nohynek, G.; Sanderink, G.J.; Lavelle, F. Docetaxel: a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 1995, 6, 339-368.
2. van Oosterom, A.T.; Schrijvers, D.; Schrijvers, D. Docetaxel, a review of preclinical and clinical experience. Part II: clinical experience. Anticancer Drugs 1995, 6, 356-368.
3. Bissery, M.C.; Guenard, D.; Gueritte-Voegelein, F.; Lavelle F. Experimental antitumor activity of Taxotere, a taxol analogue. Cancer Res. 1991, 51, 4845-4852.
4. Boven, E.; Venema-Gaberscek, E.; Erkelens, C.A. Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer. Ann. Oncol. 1994, 4, 321-324.
5. Fulton, B.; Spencer, C.M. Docetaxel A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs 1996, 51, 1075-1092.
6. Crommentuyn, K.M.; Schellens, J.H.; van den Berg, J.D.; Beijnen, J.H. In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide. Cancer Treat. Rev. 1998, 24, 345-366.
7. Rivory, L.P.; Bowles, M.R.; Robert, J.; Pond, S.M. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem. Pharmacol. 1996, 52, 1103-1111.
8. Pommier, Y. Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Sem. Oncol. 1996, 23, 3-10.
9. Masuda, N.; Fukuoka, M.; Kusunoki, Y.; Matsui, K.; Takifuji, N.; Kudoh, S.; Negoro, S.; Nishioka, M.;, Nakagawa, K.; Takada M. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol. 1992, 10, 1225-1229.
10. Rothenberg, M.L. CPT-11: An original spectrum of clinical activity. Sem. Oncol. 1996, 23, 21-26.
11. Chou, T.C.; Motzer, R.; Tong, Y.; Bosl, G.J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer Inst. 1994, 86, 1517-1524.
12. Kaufmann, S.H.; Peereboom, D.; Buckwalter, C.A.; Svingen, P.A.; Grochow, L.B.; Donehower, R.C.; Rowinsky, E.K. Cytotoxiceffects of topotecan combined with various anticancer agents in human cancer cell lines. J. Natl. Cancer Inst. 1996, 88, 734-741.
13. Pitot, H.C.; Erlichman, C., Goldberg, R.M. Phase I trial of irinotecan (CPT-11) given once every three weeks to patients with advanced solid tumors. Proc. Amer. Soc. Clin. Oncol. 1996, 15, 1581.
14. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000, 92, 205-16.
15. Duffy, D.E.; Santner, T.J. Confidence intervals for a binomial parameter based on multistage tests. Biometrics 1987, 43, 81-93.
16. Kaplan, E.; Meier, P. Nonparametric estimation from incomplete observation. J. Am. Statist. Assoc. 1958, 53, 456-481.
17. Sandler, A.; van Oosterom, A.T. Irinotecan in cancers of the lung and cervix. Anti-Cancer Drugs 1999, 10, S13-17.
18. Negoro, S.; Fukuoka, M.; Niitani, H.; Suzuki, A.; Nakabayashi, T.; Kimura, M.; Motomiya, M.; Kurita, Y.; Hasegawa, K.; Kuriyama, T. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 co-operative group. Jpn. J. Cancer Chemother 1991, 18, 1013-1019.
19. Nakai, H.; Fukuoka, M.; Furuse, K.; Nakao, I.; Yoshimori, K.; Ogura, T.; Hara, N.; Sakata, Y.; Saito, H.; Hasegawa, K. An early phase II study of CPT-11 for primary lung cancer. Jpn. J. Cancer Chemother 1991, 18, 607-612.
20. Nakanishi, Y.; Takayama, K.; Takano, K.; Inoue, K.; Osaki, S.; Wataya, H.; Takaki, Y.; Minami, T.; Kawasaki, M.; Hara N. Secondline chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. Am. J. Clin. Oncol. 1999, 22, 399-402.
21. Han, J.Y.; Lee, D.H.; Kim, H.Y.; Kim, E.A.; Lee, J.J.; Ju, S.Y.; Shin, E.H.; Lee, J.S. A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer. Clin. Cancer Res. 2003, 9, 5909-5914.
22. Androulakis, N.; Kouroussis, C.; Kakolyris, S.; Tzannes, S.; Papadakis, E.; Papadimitriou, C.; Geroyianni, A.; Georgopoulou, T.; Dimopoulou, I.; Souglakos, J.; Kotsakis, A.; Vardakis, N.; Hatzidaki, D.; Georgoulias, V. Salvage treatment with paclitaxel and gemcitabine for patients with non-small cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study. Ann. Oncol. 1998, 9, 1127-1130.
23. Stathopoulos, G.P.; Rigatos, S.; Malamos, N.A. Paclitaxel combined with cisplatin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cisplatin. Oncol. Rep. 1999, 6, 797-800.
24. Chang, A.Y.; DeVore, R.F.; Johnson, D. Pilot study of vinorelbine (Navelbine) and paclitaxel in patients with non-small cell lung cancer. Semin. Oncol. 1996, 23, 19-21.
25. Rosati, G.; Rossi, A.; Nicolella, G.; Panza, G. Second-line chemotherapy with paclitaxel, cisplatin and gemcitabine in pre-treated sensitive cisplatin-based patients with advanced non-small cell lung cancer. Anticancer Res. 2000, 20, 2229-2233.
26. Stewart, D.J.; Tomiac, E.M.; Goss, G.; Gertler, S.Z.; Logan, D.; Huan, S.; Yau, J.; Dulude, H.; Evans, W.K. Paclitaxel plus hydroxyurea as second-line therapy for non-small cell lung cancer. Lung. Cancer 1996, 15, 115-23.
27. Fossella, F.V.; Lee, J.S.; Shin, D.M.; Calayag, M.; Huber, M.; Perez-Soler, R.; Murphy, W.K.; Lippman, S.; Benner, S.; Glisson, B. Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer. J. Clin. Oncol. 1995, 13, 645-651.
28. Burris, H.; Eckhardt, J.; Fields, S. Phase II trials of taxotere in patients with non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 1993, 12, 35A.
29. Gandara, D.R.; Vokes, E.; Green, M. Multicenter trial of docetaxel (Taxotere) in platinum-treated non-small cell lung cancer (NSCLC): confirmation of prolonged survival. Lung Cancer 1997, 18, 21. (abstr 69).
30. Robinet, G.; Leisbauer, J.P.; Thomas, P. Phase II study of docetaxel (Taxotere) in first and second line NSCLC. Lung Cancer 1997, 18, 42. (abstr 155).
31. 2 in platinum-pretreated advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 1999, 18, 518a.
32. Alexopoulos, K.; Kouroussis, C.; Androulakis, N.; Papdakis, E.; Vaslamatzis, M.; Kakolyriss, S.; Samelis, G.; Patila, E.; Vossos, A.; Samantas, E.; Georgoulias, V. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Cancer Chemother. Pharmacol. 1999, 43, 257-62.
33. Shepherd, F.A.; Dancey, J.; Ramlau, R.; Mattson, K.; Gralla, R.; O'Rourke, M.; Levitan, N.; Gressot, L.; Vincent, M.; Burkes, R.; Coughlin, S.; Kim, Y.; Berille, J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 2000, 18, 2095-2103.
34. Fossella, F.V.; DeVore, R.; Kerr, R.N.; Crawford, J.; Natale, R.R.; Dunphy, F.; Kalman, L.; Miller, V.; Lee, J.S.; Moore, M.; Gandara, D.; Karp, D.; Vokes, E.; Kris, M.; Kim, Y.; Gamza, F.; Hammershaimb, L. Randomised phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J. Clin. Oncol. 2000, 18, 2354-2362.
35. Yamamoto, N.; Fukuoka, M.; Negoro, S.I.; Nakagawa, K.; Saito, H.; Matsui, K.; Kawahara, M.; Senba, H.; Takada, Y.; Kudoh, S.; Nakano, T.; Katakami, N.; Sugiura, T.; Hoso, T.; Ariyoshi, Y. Randomised phase II study of docetaxel/cisplatin vs. docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803). Br. J. Cancer 2004, 90, 87-92.
36. Font, A; Sanchez, J.M.; Taron, M.; Martinez-Balibrea, E.; Sanchez, J.J.; Manzano, J.L.; Margeli, M.; Richardet, M.; Barnadas, A.; Abad, A.; Rosell, R. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest. New Drugs 2003, 21, 435-443.